{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T22:59:09Z","timestamp":1788303549228,"version":"build-2803163510"},"reference-count":174,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,12,7]],"date-time":"2020-12-07T00:00:00Z","timestamp":1607299200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004442","name":"Narodowym Centrum Nauki","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004442","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004281","name":"Narodowe Centrum Nauki","doi-asserted-by":"publisher","award":["2018\/29\/B\/NZ7\/02662"],"award-info":[{"award-number":["2018\/29\/B\/NZ7\/02662"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.biopha.2020.111113","type":"journal-article","created":{"date-parts":[[2020,12,16]],"date-time":"2020-12-16T21:23:39Z","timestamp":1608153819000},"page":"111113","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"special_numbering":"C","title":["Catestatin peptide of chromogranin A as a potential new target for several risk factors management in the course of metabolic syndrome"],"prefix":"10.1016","volume":"134","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7206-7931","authenticated-orcid":false,"given":"Yasmina","family":"Bourebaba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malwina","family":"Mularczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzyzstof","family":"Marycz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynda","family":"Bourebaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2020.111113_bib0005","first-page":"1595","article-title":"Role of insulin resistance in human disease (Syndrome X): an expanded definition","volume":"37","author":"Reaven","year":"1988","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.biopha.2020.111113_bib0010","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1001\/archinte.1989.00390070054005","article-title":"The deadly quartet: upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension","volume":"149","author":"Kaplan","year":"1989","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.biopha.2020.111113_bib0015","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1051\/medsci\/200521121045","article-title":"Syndrome m\u00e9tabolique\u202f: quelle d\u00e9finition pour quel(s) traitement(s)?","volume":"21","author":"Junquero","year":"2005","journal-title":"Med. Sci. (Paris)."},{"key":"10.1016\/j.biopha.2020.111113_bib0020","doi-asserted-by":"crossref","first-page":"683","DOI":"10.2337\/diacare.24.4.683","article-title":"Cardiovascular morbidity and mortality associated with the metabolic syndrome","volume":"24","author":"Isomaa","year":"2001","journal-title":"Diabetes Care"},{"key":"10.1016\/j.biopha.2020.111113_bib0025","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.cpcardiol.2004.10.001","article-title":"New approaches in the intensive management of cardiovascular risk in the metabolic syndrome","volume":"30","author":"Rosenson","year":"2005","journal-title":"Curr. Prob. Cardiol."},{"key":"10.1016\/j.biopha.2020.111113_bib0030","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1741-7015-9-48","article-title":"Metabolic syndrome: definitions and controversies","volume":"9","author":"Kassi","year":"2011","journal-title":"BMC Med."},{"key":"10.1016\/j.biopha.2020.111113_bib0035","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.3390\/jcm9051294","article-title":"Inhibition of protein-tyrosine phosphatase PTP1B and LMPTP promotes Palmitate\/Oleate-Challenged HepG2 cell survival by reducing lipoapoptosis, improving mitochondrial dynamics and mitigating oxidative and endoplasmic reticulum stress","volume":"9","author":"Bourebaba","year":"2020","journal-title":"JCM"},{"key":"10.1016\/j.biopha.2020.111113_bib0040","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1210\/er.2008-0024","article-title":"The metabolic syndrome","volume":"29","author":"Cornier","year":"2008","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.biopha.2020.111113_bib0045","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.jacc.2015.06.1328","article-title":"The CardioMetabolic health alliance","volume":"66","author":"Sperling","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.biopha.2020.111113_bib0050","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1177\/1479164119827611","article-title":"Insulin resistance and insulin hypersecretion in the metabolic syndrome and type 2 diabetes: time for a conceptual framework shift","volume":"16","author":"Nolan","year":"2019","journal-title":"Diabetes Vasc. Dis. Res."},{"key":"10.1016\/j.biopha.2020.111113_bib0055","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/jvim.15423","article-title":"ECEIM consensus statement on equine metabolic syndrome","volume":"33","author":"Durham","year":"2019","journal-title":"J. Vet. Intern. Med."},{"key":"10.1016\/j.biopha.2020.111113_bib0060","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/S0140-6736(05)66378-7","article-title":"The metabolic syndrome","volume":"365","author":"Eckel","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2020.111113_bib0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2016\/3718468","article-title":"Macroautophagy and selective mitophagy ameliorate chondrogenic differentiation potential in adipose stem cells of equine metabolic syndrome: new findings in the field of progenitor cells differentiation","volume":"2016","author":"Marycz","year":"2016","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.biopha.2020.111113_bib0070","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1038\/sj.ijo.0800770","article-title":"Adipose tissue as an endocrine and paracrine organ","volume":"22","author":"Mohamed-Ali","year":"1998","journal-title":"Int. J. Obes."},{"key":"10.1016\/j.biopha.2020.111113_bib0075","first-page":"204","article-title":"Metabolic syndrome: What are the risks for humans?","volume":"4","author":"Gupta","year":"2010","journal-title":"Biosci. Trends"},{"key":"10.1016\/j.biopha.2020.111113_bib0080","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/j.1749-6632.1999.tb07793.x","article-title":"Molecular mechanism of metabolic syndrome X: contribution of Adipocytokines. Adipocyte-derived Bioactive Substances","volume":"892","author":"Matsuzawa","year":"1999","journal-title":"Annals NY Acad. Sci."},{"key":"10.1016\/j.biopha.2020.111113_bib0085","doi-asserted-by":"crossref","first-page":"391","DOI":"10.2217\/dmt.14.30","article-title":"Obesity and metabolic syndrome: the contribution of visceral fat and adiponectin","volume":"4","author":"Matsuzawa","year":"2014","journal-title":"Diabetes Manag."},{"key":"10.1016\/j.biopha.2020.111113_bib0090","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1194\/jlr.R200009-JLR200","article-title":"Hormone-sensitive lipase: control of intracellular tri-(di-)acylglycerol and cholesteryl ester hydrolysis","volume":"43","author":"Kraemer","year":"2002","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.biopha.2020.111113_bib0095","doi-asserted-by":"crossref","first-page":"40236","DOI":"10.1074\/jbc.M608048200","article-title":"Adipose triglyceride lipase and hormone-sensitive lipase are the major enzymes in adipose tissue triacylglycerol catabolism","volume":"281","author":"Schweiger","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2020.111113_bib0100","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1210\/jc.2006-1318","article-title":"Adipose triglyceride lipase and hormone-sensitive lipase protein expression is decreased in the obese insulin-resistant state","volume":"92","author":"Jocken","year":"2007","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.biopha.2020.111113_bib0105","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s13287-019-1292-z","volume":"10","author":"Bourebaba","year":"2019","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.biopha.2020.111113_bib0110","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3390\/md15080237","article-title":"Spirulina platensis improves mitochondrial function impaired by elevated oxidative stress in adipose-derived mesenchymal stromal cells (ASCs) and intestinal epithelial cells (IECs), and enhances insulin sensitivity in equine metabolic syndrome (EMS) horses","volume":"15","author":"Nawrocka","year":"2017","journal-title":"Mar. Drugs"},{"key":"10.1016\/j.biopha.2020.111113_bib0115","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1042\/BJ20130457","article-title":"Brown adipose tissue: development, metabolism and beyond","volume":"453","author":"Schulz","year":"2013","journal-title":"Biochem. J."},{"key":"10.1016\/j.biopha.2020.111113_bib0120","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/s11684-017-0555-2","article-title":"Role of brown adipose tissue in metabolic syndrome, aging, and cancer cachexia","volume":"12","author":"Dong","year":"2018","journal-title":"Front Med."},{"key":"10.1016\/j.biopha.2020.111113_bib0125","first-page":"412","article-title":"Emergence of brown adipocytes in white fat in mice is under genetic control","volume":"102","author":"Guerra","year":"1998","journal-title":"Effects on body weight and adiposity, J Clin Invest."},{"key":"10.1016\/j.biopha.2020.111113_bib0130","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1073\/pnas.0610416104","article-title":"Ectopic brown adipose tissue in muscle provides a mechanism for differences in risk of metabolic syndrome in mice","volume":"104","author":"Almind","year":"2007","journal-title":"Proc Natl Acad Sci."},{"key":"10.1016\/j.biopha.2020.111113_bib0135","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1172\/JCI13103","article-title":"Brown adipose tissue\u2013specific insulin receptor knockout shows diabetic phenotype without insulin resistance","volume":"108","author":"Guerra","year":"2001","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.biopha.2020.111113_bib0140","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.jevs.2008.10.016","article-title":"Metabolic predispositions to laminitis in horses and ponies: obesity, insulin resistance and metabolic syndromes","volume":"28","author":"Geor","year":"2008","journal-title":"J. Equine Vet. Sci."},{"key":"10.1016\/j.biopha.2020.111113_bib0145","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s40273-014-0243-x","article-title":"The epidemiology of obesity: a big picture","volume":"33","author":"Hruby","year":"2015","journal-title":"Pharmaco. Econ."},{"key":"10.1016\/j.biopha.2020.111113_bib0150","doi-asserted-by":"crossref","DOI":"10.1111\/evj.12008","article-title":"Fight the fat!: Fight the fat!","volume":"45","author":"Owers","year":"2013","journal-title":"Equine Vet. J."},{"key":"10.1016\/j.biopha.2020.111113_bib0155","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s11892-003-0057-2","article-title":"Epidemiology of the insulin resistance syndrome","volume":"3","author":"Meigs","year":"2003","journal-title":"Curr. Diab. Rep."},{"key":"10.1016\/j.biopha.2020.111113_bib0160","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1016\/S0140-6736(17)30058-2","article-title":"Type 2 diabetes","volume":"389","author":"Chatterjee","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2020.111113_bib0165","doi-asserted-by":"crossref","first-page":"237","DOI":"10.4158\/EP.9.S2.5","article-title":"American College of Endocrinology position statement on the insulin resistance syndrome","volume":"9","author":"Einhorn","year":"2003","journal-title":"Endocr. Pract."},{"key":"10.1016\/j.biopha.2020.111113_bib0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2017\/1478294","article-title":"Insulin resistance, type 1 and type 2 diabetes, and related complications 2017","volume":"2017","author":"Ndisang","year":"2017","journal-title":"J. Diabetes Res."},{"key":"10.1016\/j.biopha.2020.111113_bib0175","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1172\/JCI10762","article-title":"Insulin resistance and cardiovascular disease","volume":"106","author":"Ginsberg","year":"2000","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.biopha.2020.111113_bib0180","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1046\/j.1464-5491.2003.01068.x","article-title":"The Metabolic Syndrome is an independent predictor of cardiovascular disease in Type 2 diabetic subjects. Prospective data from the Verona Diabetes Complications Study","volume":"21","author":"Bonora","year":"2004","journal-title":"Diabet. Med."},{"key":"10.1016\/j.biopha.2020.111113_bib0185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2017\/6425359","article-title":"Insulin resistance and chronic kidney disease in patients with type 1 diabetes mellitus","volume":"2017","author":"Vladu","year":"2017","journal-title":"J. Nutr. Metab."},{"key":"10.1016\/j.biopha.2020.111113_bib0190","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1159\/000479801","article-title":"Insulin Resistance in Kidney Disease: Is There a Distinct Role Separate from That of Diabetes or Obesity?","volume":"8","author":"Whaley-Connell","year":"2018","journal-title":"Cardiorenal. Med."},{"key":"10.1016\/j.biopha.2020.111113_bib0195","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/0002-9343(88)90401-9","article-title":"Cellular mechanisms of insulin resistance in non-insulin-dependent (type II) diabetes","volume":"85","author":"Olefsky","year":"1988","journal-title":"Am. J. Med."},{"key":"10.1016\/j.biopha.2020.111113_bib0200","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1172\/JCI115997","article-title":"Increased rate of Gluconeogenesis in type 11 diabetes mellitus","volume":"90","author":"Magnusson","year":"1992","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.biopha.2020.111113_bib0205","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMp068177","article-title":"Obesity and diabetes in the Developing World \u2014 a growing challenge","volume":"356","author":"Parvez","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2020.111113_bib0210","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1124\/jpet.109.164871","article-title":"Heme arginate therapy enhanced adiponectin and atrial natriuretic peptide, but abated Endothelin-1 with attenuation of kidney histopathological lesions in mineralocorticoid-induced hypertension","volume":"334","author":"Ndisang","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.biopha.2020.111113_bib0215","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1080\/17512433.2018.1429910","article-title":"The pharmacological management of metabolic syndrome","volume":"11","author":"Rask Larsen","year":"2018","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"10.1016\/j.biopha.2020.111113_bib0220","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1042\/CS20050208","article-title":"Molecular genetics of human hypertension","volume":"110","author":"Gong","year":"2006","journal-title":"Clin. Sci."},{"key":"10.1016\/j.biopha.2020.111113_bib0225","first-page":"569","article-title":"Global burden of cardiovascular disease and stroke: hypertension at the core","volume":"31","author":"Lackland","year":"2015","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.biopha.2020.111113_bib0230","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1080\/10641963.2016.1210629","article-title":"Metabolic syndrome, hypertension, and nervous system injury: epidemiological correlates","volume":"39","author":"Ricci","year":"2017","journal-title":"Clin. Exp. Hypertens."},{"key":"10.1016\/j.biopha.2020.111113_bib0235","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.3109\/10641969909061028","article-title":"1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension","volume":"21","author":"WHOISHGLH","year":"1999","journal-title":"Clin. Exp. Hypertens."},{"key":"10.1016\/j.biopha.2020.111113_bib0240","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1097\/HJH.0b013e3281fc975a","article-title":"2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)","volume":"25","author":"Mancia","year":"2007","journal-title":"J. Hypertens."},{"key":"10.1016\/j.biopha.2020.111113_bib0245","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2165\/00151642-200815020-00003","article-title":"The clinical significance of metabolic syndrome in hypertension: metabolic syndrome increases cardiovascular risk: the pro position","volume":"15","author":"de la Sierra","year":"2009","journal-title":"High Blood Press. Cardiovasc. Prev."},{"key":"10.1016\/j.biopha.2020.111113_bib0250","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1161\/01.HYP.11.6.573","article-title":"Endothelium-dependent responses in carotid and renal arteries of normotensive and hypertensive rats","volume":"11","author":"L\u00fcscher","year":"1988","journal-title":"Hypertension"},{"key":"10.1016\/j.biopha.2020.111113_bib0255","doi-asserted-by":"crossref","first-page":"S190","DOI":"10.1097\/00005344-199204002-00053","article-title":"Endothelial dysfunction of resistance arteries of spontaneously hypertensive rats","volume":"20","author":"Fu-Xiang","year":"1992","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.biopha.2020.111113_bib0260","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1161\/01.CIR.87.5.1468","article-title":"Role of endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension","volume":"87","author":"Panza","year":"1993","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2020.111113_bib0265","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1161\/01.CIR.91.6.1732","article-title":"Impaired endothelium-dependent vasodilation in patients with essential hypertension: evidence that nitric oxide abnormality is not localized to a single signal transduction pathway","volume":"91","author":"Panza","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2020.111113_bib0270","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/00000441-200512000-00008","article-title":"Hypertension and the metabolic syndrome","volume":"330","author":"Morse","year":"2005","journal-title":"Am. J. M. Sc."},{"key":"10.1016\/j.biopha.2020.111113_bib0275","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1507\/endocrj.EJ14-0471","article-title":"A common genetic variant of the chromogranin A-derived peptide catestatin is associated with atherogenesis and hypertension in a Japanese population","volume":"62","author":"Choi","year":"2015","journal-title":"Endocr. J."},{"key":"10.1016\/j.biopha.2020.111113_bib0280","doi-asserted-by":"crossref","first-page":"841","DOI":"10.2337\/db17-0788","article-title":"Catestatin inhibits obesity-induced macrophage infiltration and inflammation in the liver and suppresses hepatic glucose production, leading to improved insulin sensitivity","volume":"67","author":"Ying","year":"2018","journal-title":"Diabetes"},{"key":"10.1016\/j.biopha.2020.111113_bib0285","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.csbj.2020.02.005","article-title":"Catestatin improves insulin sensitivity by attenuating endoplasmic reticulum stress: in vivo and in silico validation","volume":"18","author":"Dasgupta","year":"2020","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"10.1016\/j.biopha.2020.111113_bib0290","first-page":"1091","article-title":"Prevention of diabetes development in those with the metabolic syndrome","volume":"91","author":"Tupper","year":"2007","journal-title":"Med. Clin. N."},{"key":"10.1016\/j.biopha.2020.111113_bib0295","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.diabet.2007.08.001","article-title":"A review of the metabolic syndrome","volume":"33","author":"Balkau","year":"2007","journal-title":"Diabetes Metab."},{"key":"10.1016\/j.biopha.2020.111113_bib0300","article-title":"Pharmacotherapy for hypertension in adults aged 18 to 59 years","volume":"8","author":"Musini","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.biopha.2020.111113_bib0305","article-title":"First-line drugs for hypertension","volume":"4","author":"Wright","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.biopha.2020.111113_bib0310","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.trsl.2015.06.017","article-title":"Targeting inflammation in metabolic syndrome","volume":"167","author":"Welty","year":"2016","journal-title":"Transl. Res."},{"key":"10.1016\/j.biopha.2020.111113_bib0315","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/379093","article-title":"Physical activity increases the total number of bone-marrow-Derived mesenchymal stem cells, enhances their osteogenic potential, and inhibits their adipogenic properties","volume":"2015","author":"Mar\u0119dziak","year":"2015","journal-title":"Stem Cells Int."},{"key":"10.1016\/j.biopha.2020.111113_bib0320","doi-asserted-by":"crossref","first-page":"314","DOI":"10.2460\/ajvr.71.3.314","article-title":"Effects of exercise training on adiposity, insulin sensitivity, and plasma hormone and lipid concentrations in overweight or obese, insulin-resistant horses","volume":"71","author":"Carter","year":"2010","journal-title":"Am. J. Vet. Res."},{"key":"10.1016\/j.biopha.2020.111113_bib0325","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1519\/JSC.0b013e31827da2f0","article-title":"Effect of intensity of aerobic training on insulin Sensitivity\/Resistance in recreationally active adults","volume":"27","author":"Grieco","year":"2013","journal-title":"J. Strength Cond. Res."},{"key":"10.1016\/j.biopha.2020.111113_bib0330","doi-asserted-by":"crossref","first-page":"222S","DOI":"10.1592\/phco.26.12part2.222S","article-title":"Metabolic syndrome treatment strategies","volume":"26","author":"Fujioka","year":"2006","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.biopha.2020.111113_bib0335","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1097\/01.pap.0000249936.05650.0c","article-title":"Metabolic Syndrome: Treatment of Hypertensive Patients","volume":"14","author":"Israili","year":"2007","journal-title":"Am. J. Ther."},{"key":"10.1016\/j.biopha.2020.111113_bib0340","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1056\/NEJM199602293340906","article-title":"Metformin","volume":"334","author":"Bailey","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2020.111113_bib0345","first-page":"436","article-title":"Clinical Inquiry: Does metformin prevent diabetes in at-risk adults?","volume":"62","author":"Mangahas","year":"2013","journal-title":"J. Fam. Pract."},{"key":"10.1016\/j.biopha.2020.111113_bib0350","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1056\/NEJMra041001","article-title":"Thiazolidinediones","volume":"351","author":"Yki-J\u00e4rvinen","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2020.111113_bib0355","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1161\/01.CIR.0000165072.01672.21","article-title":"Pioglitazone Decreases Carotid Intima-Media Thickness Independently of Glycemic Control in Patients With Type 2 Diabetes Mellitus: Results From a Controlled Randomized Study","volume":"111","author":"Langenfeld","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2020.111113_bib0360","doi-asserted-by":"crossref","first-page":"708","DOI":"10.2337\/diacare.25.4.708","article-title":"A Prospective, Randomized Comparison of the Metabolic Effects of Pioglitazone or Rosiglitazone in Patients With Type 2 Diabetes Who Were Previously Treated With Troglitazone","volume":"25","author":"Khan","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1016\/j.biopha.2020.111113_bib0365","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1161\/CIRCULATIONAHA.105.169404","article-title":"Diagnosis and management of the metabolic syndrome: an american heart Association\/National heart, lung, and blood institute scientific statement","volume":"112","author":"Grundy","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2020.111113_bib0370","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","volume":"289","author":"Chobanian","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.biopha.2020.111113_bib0375","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJM200003303421301","article-title":"Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus","volume":"342","author":"Gress","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2020.111113_bib0380","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1007\/s11906-015-0558-9","article-title":"Anti-hypertensive drug treatment of patients with and the metabolic syndrome and obesity: a review of evidence, meta-analysis, post hoc and guidelines publications","volume":"17","author":"Owen","year":"2015","journal-title":"Curr. Hypertens. Rep."},{"key":"10.1016\/j.biopha.2020.111113_bib0385","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1056\/NEJMoa042274","article-title":"Angiotensin-receptor blockade versus converting\u2013Enzyme inhibition in type 2 diabetes and nephropathy","volume":"351","author":"Barnett","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2020.111113_bib0390","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.2165\/00003495-200464220-00004","article-title":"Prevention of type 2 diabetes mellitus through inhibition of the renin-angiotensin system","volume":"64","author":"Scheen","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/j.biopha.2020.111113_bib0395","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0002-9149(03)00228-5","article-title":"Debate: angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers\u2014a gap in evidence-based medicine","volume":"91","author":"Ball","year":"2003","journal-title":"Am J Card."},{"key":"10.1016\/j.biopha.2020.111113_bib0400","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","article-title":"Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)","volume":"288","author":"The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.biopha.2020.111113_bib0405","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/414821a","article-title":"New drug targets for type 2 diabetes and the metabolic syndrome","volume":"414","author":"Moller","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2020.111113_bib0410","doi-asserted-by":"crossref","first-page":"525","DOI":"10.2174\/1389450054021972","article-title":"Adipokines: Therapeutic Targets for Metabolic Syndrome","volume":"6","author":"Kobayashi","year":"2005","journal-title":"CDT"},{"key":"10.1016\/j.biopha.2020.111113_bib0415","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0167-0115(83)90145-3","article-title":"Chromogranin: widespread immunoreactivity in polypeptide hormone producing tissues and in serum","volume":"6","author":"O\u2019Connor","year":"1983","journal-title":"Regul. Pept."},{"key":"10.1016\/j.biopha.2020.111113_bib0420","doi-asserted-by":"crossref","first-page":"11559","DOI":"10.1016\/S0021-9258(18)37995-X","article-title":"Molecular cloning and primary structure of human chromogranin A (secretory protein I) cDNA","volume":"263","author":"Helman","year":"1988","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2020.111113_bib0425","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/0167-0115(95)00069-N","article-title":"Chromogranin A: current status as a precursor for bioactive peptides and a granulogenic\/sorting factor in the regulated secretory pathway","volume":"58","author":"Iacangelo","year":"1995","journal-title":"Regul. Pept."},{"key":"10.1016\/j.biopha.2020.111113_bib0430","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1056\/NEJMra021405","article-title":"The chromogranin\u2013Secretogranin family","volume":"348","author":"Taupenot","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2020.111113_bib0435","doi-asserted-by":"crossref","first-page":"598","DOI":"10.5603\/EP.a2018.0052","article-title":"Chromogranin-A and its role in the pathogenesis of diabetes mellitus","volume":"69","author":"Herold","year":"2018","journal-title":"Endokrynol. Pol."},{"key":"10.1016\/j.biopha.2020.111113_bib0440","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/215058a0","article-title":"Secretion of a chromaffin granule protein, chromogranin, from the adrenal gland after splanchnic stimulation","volume":"215","author":"Blaschko","year":"1967","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2020.111113_bib0445","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0088698","article-title":"Characterization and plasma measurement of the WE-14 peptide in patients with pheochromocytoma","volume":"9","author":"Guillemot","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2020.111113_bib0450","doi-asserted-by":"crossref","first-page":"40C","DOI":"10.1042\/bj0970040C","article-title":"The release of protein from the stimulated adrenal medulla","volume":"97","author":"Banks","year":"1965","journal-title":"Biochem. J."},{"key":"10.1016\/j.biopha.2020.111113_bib0455","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5114\/aoms.2016.57577","article-title":"Chromogranin A \u2013 unspecific neuroendocrine marker. Clinical utility and potential diagnostic pitfalls","volume":"1","author":"Gut","year":"2016","journal-title":"AOMS"},{"key":"10.1016\/j.biopha.2020.111113_bib0460","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/0306-4522(76)90001-4","article-title":"The composition of adrenal chromaffin granules: an assessment of controversial results","volume":"1","author":"Winkler","year":"1976","journal-title":"Neuroscience"},{"key":"10.1016\/j.biopha.2020.111113_bib0465","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1161\/01.HYP.15.3.237","article-title":"Storage and release in hypertension","volume":"15","author":"Takiyyuddin","year":"1990","journal-title":"Hypertension"},{"key":"10.1016\/j.biopha.2020.111113_bib0470","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1161\/01.CIR.81.1.185","article-title":"Is physiologic sympathoadrenal catecholamine release exocytotic in humans?","volume":"81","author":"Takiyyuddin","year":"1990","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2020.111113_bib0475","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/0306-4522(92)90222-N","article-title":"The chromogranins A and B: the first 25 years and future perspectives","volume":"49","author":"Winkler","year":"1992","journal-title":"Neuroscience"},{"key":"10.1016\/j.biopha.2020.111113_bib0480","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1748-1716.2007.01806.x","article-title":"Chromogranins A. and B and secretogranin II: evolutionary and functional aspects: Evolution and function of granins","volume":"192","author":"Montero-Hadjadje","year":"2008","journal-title":"Acta Physiol."},{"key":"10.1016\/j.biopha.2020.111113_bib0485","doi-asserted-by":"crossref","first-page":"17026","DOI":"10.1016\/S0021-9258(18)45486-5","article-title":"The Primary Structure of HumanChromogranin A and Pancreastatin\u201d","volume":"262","author":"Konecki","year":"1987","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2020.111113_bib0490","doi-asserted-by":"crossref","first-page":"10999","DOI":"10.1021\/bi700704r","article-title":"Biogenesis of the secretory granule: chromogranin a coiled-Coil structure results in unusual physical properties and suggests a mechanism for granule core condensation","volume":"46","author":"Mosley","year":"2007","journal-title":"Biochemistry"},{"key":"10.1016\/j.biopha.2020.111113_bib0495","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/bj2620001","article-title":"Biochemistry of the chromogranin A protein family","volume":"262","author":"Simon","year":"1989","journal-title":"Biochem. J."},{"key":"10.1016\/j.biopha.2020.111113_bib0500","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1432-1033.1993.tb18240.x","article-title":"Intracellular and extracellular processing of chromogranin A. Determination of cleavage sites","volume":"217","author":"Metz-Boutigue","year":"1993","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.biopha.2020.111113_bib0505","doi-asserted-by":"crossref","first-page":"6938","DOI":"10.1021\/bi0300433","article-title":"Primary sequence characterization of catestatin intermediates and peptides defines proteolytic cleavage sites utilized for converting chromogranin a into active catestatin secreted from neuroendocrine chromaffin cells","volume":"42","author":"Lee","year":"2003","journal-title":"Biochemistry"},{"key":"10.1016\/j.biopha.2020.111113_bib0510","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/nyas.14249","article-title":"Chromogranin A and its fragments in cardiovascular, immunometabolic, and cancer regulation","volume":"1455","author":"Mahata","year":"2019","journal-title":"Ann. NY Acad. Sci."},{"key":"10.1016\/j.biopha.2020.111113_bib0515","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1002\/j.1460-2075.1986.tb04388.x","article-title":"The primary structure of bovine chromogranin A: a representative of a class of acidic secretory proteins common to a variety of peptidergic cells","volume":"5","author":"Benedum","year":"1986","journal-title":"EMBO J."},{"key":"10.1016\/j.biopha.2020.111113_bib0520","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/323082a0","article-title":"Bovine chromogranin A sequence and distribution of its messenger RNA in endocrine tissues","volume":"323","author":"Iacangelo","year":"1986","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2020.111113_bib0525","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0014-5793(88)80880-9","article-title":"Primary structure of rat chromogranin A and distribution of its mRNA","volume":"227","author":"Iacangelo","year":"1988","journal-title":"FEBS Lett."},{"key":"10.1016\/j.biopha.2020.111113_bib0530","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1161\/01.HYP.14.4.435","article-title":"Molecular cloning of chromogranin A from rat pheochromocytoma cells","volume":"14","author":"Parmer","year":"1989","journal-title":"Hypertension"},{"key":"10.1016\/j.biopha.2020.111113_bib0535","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1210\/endo-122-5-2339","article-title":"The sequence of porcine chromogranin a messenger rna demonstrates chromogranin A can serve as the precursor for the biologically active hormone, pancreastatin","volume":"122","author":"Iacangelo","year":"1988","journal-title":"Endocrinology"},{"key":"10.1016\/j.biopha.2020.111113_bib0540","doi-asserted-by":"crossref","first-page":"13130","DOI":"10.1016\/S0021-9258(18)98814-9","article-title":"Structure and function of the chromogranin A gene. Clues to evolution and tissue-specific expression","volume":"266","author":"Wu","year":"1991","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2020.111113_bib0545","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1093\/cvr\/cvn155","article-title":"Catestatin is a novel endogenous peptide that regulates cardiac function and blood pressure","volume":"80","author":"Mahapatra","year":"2008","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.biopha.2020.111113_bib0550","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1056\/NEJM198409203111204","article-title":"Radioimmunoassay of chromogranin a in plasma as a measure of exocytotic sympathoadrenal activity in normal subjects and patients with pheochromocytoma","volume":"311","author":"O\u2019Connor","year":"1984","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2020.111113_bib0555","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1210\/edrv-12-2-181","article-title":"Chromogranin A: Its Role in Endocrine Function and as an Endocrine and Neuroendocrine Tumor Marker","volume":"12","author":"Deftos","year":"1991","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.biopha.2020.111113_bib0560","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/BF03347721","article-title":"The granin protein family: markers for neuroendocrine cells and tools for the diagnosis of neuroendocrine tumors","volume":"17","author":"Rosa","year":"1994","journal-title":"J. Endocrinol. Invest."},{"key":"10.1016\/j.biopha.2020.111113_bib0565","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1046\/j.1365-2362.1998.00305.x","article-title":"Chromogranin A: its clinical value as marker of neuroendocrine tumours","volume":"28","author":"Nobels","year":"1998","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.biopha.2020.111113_bib0570","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00441-002-0625-9","article-title":"Localization and characterization of evolutionarily conserved chromogranin A-derived peptides in the rat and human pituitary and adrenal glands","volume":"310","author":"Montero-Hadjadje","year":"2002","journal-title":"Cell Tissue Res."},{"key":"10.1016\/j.biopha.2020.111113_bib0575","series-title":"Chromogranins","first-page":"3","article-title":"The chromogranins","author":"Helle","year":"2002"},{"key":"10.1016\/j.biopha.2020.111113_bib0580","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1245\/s10434-010-1006-3","article-title":"Chromogranin a\u2014biological function and clinical utility in neuro endocrine tumor disease","volume":"17","author":"Modlin","year":"2010","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.biopha.2020.111113_bib0585","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0092-8674(01)00459-7","article-title":"Chromogranin a, an \u201cOn\/Off\u201d switch controlling dense-core secretory granule biogenesis","volume":"106","author":"Kim","year":"2001","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2020.111113_bib0590","doi-asserted-by":"crossref","first-page":"R45","DOI":"10.1530\/EC-14-0027","article-title":"Biological function and clinical relevance of chromogranin A and derived peptides","volume":"3","author":"D\u2019amico","year":"2014","journal-title":"Endocr. Connect."},{"key":"10.1016\/j.biopha.2020.111113_bib0595","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1007\/s10571-010-9564-2","article-title":"Inositol 1,4,5-trisphosphate receptor in chromaffin secretory granules and its relation to chromogranins","volume":"30","author":"Yoo","year":"2010","journal-title":"Cell. Mol. Neurobiol."},{"key":"10.1016\/j.biopha.2020.111113_bib0600","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s12031-012-9728-2","article-title":"Chromogranin a and derived peptides in health and disease","volume":"48","author":"Loh","year":"2012","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.biopha.2020.111113_bib0605","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.3389\/fimmu.2018.02199","article-title":"G. Van Den Bogaart, Catestatin as a target for treatment of inflammatory diseases","volume":"9","author":"Muntjewerff","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2020.111113_bib0610","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1172\/JCI118760","article-title":"Chromogranin A processing and secretion: specific role of endogenous and exogenous prohormone convertases in the regulated secretory pathway","volume":"98","author":"Eskeland","year":"1996","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.biopha.2020.111113_bib0615","doi-asserted-by":"crossref","first-page":"25022","DOI":"10.1074\/jbc.M101545200","article-title":"Proteolytic Cleavage of Chromogranin A (CgA) by Plasmin: selective liberation of a specific bioactive CgA fragment that regulates catecholamine release","volume":"276","author":"Jiang","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2020.111113_bib0620","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1210\/en.2007-0838","article-title":"Proteolytic cleavage of human chromogranin a containing naturally occurring catestatin variants: differential processing at Catestatin Region by plasmin","volume":"149","author":"Biswas","year":"2008","journal-title":"Endocrinology"},{"key":"10.1016\/j.biopha.2020.111113_bib0625","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1210\/en.2008-1613","article-title":"Cathepsin l colocalizes with chromogranin a in chromaffin vesicles to generate active peptides","volume":"150","author":"Biswas","year":"2009","journal-title":"Endocrinology"},{"key":"10.1016\/j.biopha.2020.111113_bib0630","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1182\/blood-2012-05-430314","article-title":"A new chromogranin A\u2013dependent angiogenic switch activated by thrombin","volume":"121","author":"Crippa","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2020.111113_bib0635","doi-asserted-by":"crossref","DOI":"10.1093\/hmg\/ddw380","article-title":"Identification of novel loci affecting circulating chromogranins and related peptides","author":"Benyamin","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.biopha.2020.111113_bib0640","doi-asserted-by":"crossref","first-page":"H2906","DOI":"10.1152\/ajpheart.01253.2006","article-title":"Endothelium-derived nitric oxide mediates the antiadrenergic effect of human vasostatin-1 in rat ventricular myocardium","volume":"292","author":"Gallo","year":"2007","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.biopha.2020.111113_bib0645","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1210\/endo.133.2.8344192","article-title":"Parastatin (porcine chromogranin A347-419), a novel chromogranin A-derived peptide, inhibits parathyroid cell secretion","volume":"133","author":"Fasciotto","year":"1993","journal-title":"Endocrinology"},{"key":"10.1016\/j.biopha.2020.111113_bib0650","doi-asserted-by":"crossref","first-page":"22905","DOI":"10.1074\/jbc.M001232200","article-title":"Formation of the Catecholamine Release-inhibitory Peptide Catestatin from Chromogranin A: determination of proteolytic cleavage sites in hormone storage granules","volume":"275","author":"Taylor","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2020.111113_bib0655","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.pneurobio.2017.04.003","article-title":"Granin-derived peptides","volume":"154","author":"Troger","year":"2017","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.biopha.2020.111113_bib0660","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1093\/abbs\/gmx083","article-title":"Role of the neuroendocrine antimicrobial peptide catestatin in innate immunity and pain","volume":"49","author":"Deng","year":"2017","journal-title":"Acta Biochim. Biophys. Sin."},{"key":"10.1016\/j.biopha.2020.111113_bib0665","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0968-0004(91)90012-K","article-title":"The granin-(chromogranin\/secretogranin) family","volume":"16","author":"Huttner","year":"1991","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.biopha.2020.111113_bib0670","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1365-2567.2010.03395.x","article-title":"Catestatin, a neuroendocrine antimicrobial peptide, induces human mast cell migration, degranulation and production of cytokines and chemokines: Catestatin activates human mast cells","volume":"132","author":"Aung","year":"2011","journal-title":"Immunology"},{"key":"10.1016\/j.biopha.2020.111113_bib0675","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbi.2013.03.006","article-title":"Nerve-derived transmitters including peptides influence cutaneous immunology","volume":"34","author":"Madva","year":"2013","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.biopha.2020.111113_bib0680","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1172\/JCI119686","article-title":"Novel autocrine feedback control of catecholamine release. A discrete chromogranin a fragment is a noncompetitive nicotinic cholinergic antagonist","volume":"100","author":"Mahata","year":"1997","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.biopha.2020.111113_bib0685","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/sj.jid.5701225","article-title":"The neuroendocrine peptide catestatin is a cutaneous antimicrobial and induced in the skin after injury","volume":"128","author":"Radek","year":"2008","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.biopha.2020.111113_bib0690","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1073\/pnas.85.5.1712","article-title":"Secretion from chromaffin cells is controlled by chromogranin A-derived peptides","volume":"85","author":"Simon","year":"1988","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.biopha.2020.111113_bib0695","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1073\/pnas.88.4.1426","article-title":"Chromostatin, a 20-amino acid peptide derived from chromogranin A, inhibits chromaffin cell secretion","volume":"88","author":"Galindo","year":"1991","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.biopha.2020.111113_bib0700","first-page":"1525","article-title":"Primary structure and function of the catecholamine release inhibitory peptide catestatin (Chromogranin A344\u2212364): identification of amino acid residues crucial for activity","volume":"14","author":"Mahata","year":"2000","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.biopha.2020.111113_bib0705","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1242\/jcs.114389","article-title":"Molecular interactions of the physiological anti-hypertensive peptide catestatin with the neuronal nicotinic acetylcholine receptor","volume":"125","author":"Sahu","year":"2012","journal-title":"J. Cell. Sci."},{"key":"10.1016\/j.biopha.2020.111113_bib0710","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1161\/CIRCULATIONAHA.106.628859","article-title":"Catecholamine Release\u2013Inhibitory Peptide Catestatin (Chromogranin A352\u2013372): Naturally Occurring Amino Acid Variant Gly364Ser Causes Profound Changes in Human Autonomic Activity and Alters Risk for Hypertension","volume":"115","author":"Rao","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2020.111113_bib0715","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2018\/2086109","article-title":"Catestatin induces glucose uptake and GLUT4 trafficking in adult rat cardiomyocytes","volume":"2018","author":"Gallo","year":"2018","journal-title":"Biomed Res. Int."},{"key":"10.1016\/j.biopha.2020.111113_bib0720","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1086\/381399","article-title":"Both rare and common polymorphisms contribute functional variation at CHGA, a regulator of catecholamine physiology","volume":"74","author":"Wen","year":"2004","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.biopha.2020.111113_bib0725","doi-asserted-by":"crossref","first-page":"23141","DOI":"10.1074\/jbc.M111.335877","article-title":"Catestatin (Chromogranin A352\u2013372) and Novel Effects on Mobilization of Fat from Adipose Tissue through Regulation of Adrenergic and Leptin Signaling","volume":"287","author":"Bandyopadhyay","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2020.111113_bib0730","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/psc.2634","article-title":"Antioxidant properties of a human neuropeptide and its protective effect on free radical-induced DNA damage: antioxidant properties of catestatin as an endogenous neuropeptide","volume":"20","author":"Mohseni","year":"2014","journal-title":"J. Pept. Sci."},{"key":"10.1016\/j.biopha.2020.111113_bib0735","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s00018-004-4461-9","article-title":"New antimicrobial activity for the catecholamine release-inhibitory peptide from chromogranin A, CMLS","volume":"62","author":"Briolat","year":"2005","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.biopha.2020.111113_bib0740","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.2174\/092986712802430063","article-title":"Chromogranin A-Derived peptides are involved in innate immunity","volume":"19","author":"Aslam","year":"2012","journal-title":"CMC"},{"key":"10.1016\/j.biopha.2020.111113_bib0745","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/00004872-200207000-00020","article-title":"Early decline in the catecholamine release-inhibitory peptide catestatin in humans at genetic risk of hypertension","volume":"20","author":"O\u2019Connor","year":"2002","journal-title":"J. Hypertens."},{"key":"10.1016\/j.biopha.2020.111113_bib0750","doi-asserted-by":"crossref","first-page":"4780","DOI":"10.1210\/en.2008-0318","article-title":"The Antihypertensive Chromogranin A Peptide Catestatin Acts as a Novel Endocrine\/Paracrine Modulator of Cardiac Inotropism and Lusitropism","volume":"149","author":"Angelone","year":"2008","journal-title":"Endocrinology"},{"key":"10.1016\/j.biopha.2020.111113_bib0755","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/cvr\/cvr129","article-title":"A novel catestatin-induced antiadrenergic mechanism triggered by the endothelial PI3K\u2013eNOS pathway in the myocardium","volume":"91","author":"Bassino","year":"2011","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.biopha.2020.111113_bib0760","doi-asserted-by":"crossref","first-page":"5027","DOI":"10.1210\/en.2009-0429","article-title":"Global disturbances in autonomic function yield cardiovascular instability and hypertension in the chromogranin a null mouse","volume":"150","author":"Gayen","year":"2009","journal-title":"Endocrinology"},{"key":"10.1016\/j.biopha.2020.111113_bib0765","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1161\/CIRCRESAHA.110.219493","article-title":"The Neuropeptide Catestatin Acts As a Novel Angiogenic Cytokine via a Basic Fibroblast Growth Factor\u2013Dependent Mechanism","volume":"107","author":"Theurl","year":"2010","journal-title":"Circ. Res."},{"key":"10.1016\/j.biopha.2020.111113_bib0770","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1172\/JCI24354","article-title":"Hypertension from targeted ablation of chromogranin A can be rescued by the human ortholog","volume":"115","author":"Mahapatra","year":"2005","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.biopha.2020.111113_bib0775","doi-asserted-by":"crossref","first-page":"28498","DOI":"10.1074\/jbc.M109.020636","article-title":"A novel pathway of insulin sensitivity in chromogranin A null mice: a crucial role for pancreastatin in glucose homeostasis","volume":"284","author":"Gayen","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2020.111113_bib0780","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1128\/MCB.00244-16","article-title":"AMPK phosphorylates Desnutrin\/ATGL and hormone-sensitive lipase to regulate lipolysis and fatty acid oxidation within adipose tissue","volume":"36","author":"Kim","year":"2016","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.biopha.2020.111113_bib0785","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1161\/CIRCULATIONAHA.107.709105","article-title":"Heritability and genome-wide linkage in US and australian twins identify novel genomic regions controlling chromogranin a: implications for secretion and blood pressure","volume":"118","author":"O\u2019Connor","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2020.111113_bib0790","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.bcp.2014.03.003","article-title":"Catestatin decreases macrophage function in two mouse models of experimental colitis","volume":"89","author":"Rabbi","year":"2014","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.biopha.2020.111113_bib0795","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.2217\/bmm-2016-0091","article-title":"Chromogranin A as biomarker in diabetes","volume":"10","author":"Broedbaek","year":"2016","journal-title":"Biomarkers Med."},{"key":"10.1016\/j.biopha.2020.111113_bib0800","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/nri2925","article-title":"Type 2 diabetes as an inflammatory disease","volume":"11","author":"Donath","year":"2011","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.biopha.2020.111113_bib0805","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fendo.2017.00020","article-title":"Chromogranin a regulation of obesity and peripheral insulin sensitivity","volume":"8","author":"Bandyopadhyay","year":"2017","journal-title":"Front Endocrinol."},{"key":"10.1016\/j.biopha.2020.111113_bib0810","doi-asserted-by":"crossref","DOI":"10.1111\/pedi.12825","article-title":"Serum catestatin concentrations are decreased in obese children and adolescents","author":"Simunovic","year":"2019","journal-title":"Pediatr. Diabetes"},{"key":"10.1016\/j.biopha.2020.111113_bib0815","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s00018-009-0208-y","article-title":"Chromogranin A: a novel susceptibility gene for essential hypertension","volume":"67","author":"Sahu","year":"2010","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.biopha.2020.111113_bib0820","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/S0196-9781(98)00086-2","article-title":"Mechanism of cardiovascular actions of the chromogranin a fragment catestatin in vivo","volume":"19","author":"Kennedy","year":"1998","journal-title":"Peptides"},{"key":"10.1016\/j.biopha.2020.111113_bib0825","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0022-3565(24)36566-8","article-title":"Neuropeptide Y-mediated pressor responses following high-frequency stimulation of the rat sympathetic nervous system","volume":"281","author":"Kennedy","year":"1997","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.biopha.2020.111113_bib0830","doi-asserted-by":"crossref","first-page":"32058","DOI":"10.1074\/jbc.M305545200","article-title":"Catecholamine Secretory Vesicle Stimulus-Transcription Coupling in Vivo: demonstration by a novel transgenic promoter\/photoprotein reporter and inhibition of secretion and transcription by the chromogranin A fragment catestatin","volume":"278","author":"Mahata","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2020.111113_bib0835","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.brainres.2009.09.088","article-title":"Catestatin attenuates the effects of intrathecal nicotine and isoproterenol","volume":"1305","author":"Gaede","year":"2009","journal-title":"Brain Res."},{"key":"10.1016\/j.biopha.2020.111113_bib0840","doi-asserted-by":"crossref","first-page":"278","DOI":"10.3109\/10641960903265246","article-title":"Direct vasoactive effects of the chromogranin a (CHGA) peptide catestatin in humans in vivo","volume":"32","author":"Fung","year":"2010","journal-title":"Clin. Exp. Hypertens."},{"key":"10.1016\/j.biopha.2020.111113_bib0845","first-page":"40","article-title":"A functional variant in the catestatin peptide modulates the endothelial nitric oxide pathway and increases the risk for hypertension","volume":"1","author":"Kiranmayi","year":"2016","journal-title":"Adv. Cardiol. Cardiovasc. Disorder."},{"key":"10.1016\/j.biopha.2020.111113_bib0850","doi-asserted-by":"crossref","first-page":"C33","DOI":"10.1016\/j.jacc.2016.07.123","article-title":"GW27-e0952 effect of catecholamine release-inhibitory peptide catestatin on sympathetic activity of hypertension","volume":"68","author":"Jianqiang","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.biopha.2020.111113_bib0855","article-title":"Catestatin (CST) is a key mediator of the immunoendocrine regulation of cardiovascular function","author":"Ying","year":"2020","journal-title":"Physiology"},{"key":"10.1016\/j.biopha.2020.111113_bib0860","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1074\/jbc.274.5.2920","article-title":"Desensitization of Catecholamine Release: the novel catecholamine release-inhibitory peptide catestatin (chromogranin A 344\u2013364) acts at the receptor to prevent nicotinic cholinergic tolerance","volume":"274","author":"Mahata","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2020.111113_bib0865","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0167-0115(03)00069-7","article-title":"Catestatin (CgA344\u2013364) stimulates rat mast cell release of histamine in a manner comparable to mastoparan and other cationic charged neuropeptides","volume":"114","author":"Kr\u00fcger","year":"2003","journal-title":"Regul. Pept."},{"key":"10.1016\/j.biopha.2020.111113_bib0870","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1161\/ATVBAHA.106.139089","article-title":"Histamine upregulates the expression of inducible nitric oxide synthase in human intimal smooth muscle cells via histamine H1 receptor and NF-\u03baB signaling pathway","volume":"27","author":"Tanimoto","year":"2007","journal-title":"ATVB"}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332220313068?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332220313068?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T12:00:17Z","timestamp":1760097617000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332220313068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":174,"alternative-id":["S0753332220313068"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2020.111113","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Catestatin peptide of chromogranin A as a potential new target for several risk factors management in the course of metabolic syndrome","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2020.111113","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"111113"}}